Novel therapeutic approaches for small cell lung cancer: the future has arrived.
作者信息
Pietanza Maria Catherine, Rudin Charles M
出版信息
Curr Probl Cancer. 2012 May-Jun;36(3):156-73. doi: 10.1016/j.currproblcancer.2012.03.005. Epub 2012 Apr 10.
Abstract
摘要
相似文献
1
Novel therapeutic approaches for small cell lung cancer: the future has arrived.小细胞肺癌的新型治疗方法：未来已至。
Curr Probl Cancer. 2012 May-Jun;36(3):156-73. doi: 10.1016/j.currproblcancer.2012.03.005. Epub 2012 Apr 10.
2
[New European approvals: Durvalumab - In first line metastatic small-cell lung cancer].
Bull Cancer. 2020 Dec;107(12):1208-1209. doi: 10.1016/j.bulcan.2020.10.003. Epub 2020 Nov 10.
3
Proteomic markers of DNA repair and PI3K pathway activation predict response to the PARP inhibitor BMN 673 in small cell lung cancer--letter.DNA修复和PI3K通路激活的蛋白质组学标志物可预测小细胞肺癌对PARP抑制剂BMN 673的反应——信函
Clin Cancer Res. 2014 Apr 15;20(8):2236. doi: 10.1158/1078-0432.CCR-13-2679. Epub 2014 Mar 31.
4
Systemic issues in small cell lung cancer.小细胞肺癌的全身问题
Curr Probl Cancer. 2012 May-Jun;36(3):131-55. doi: 10.1016/j.currproblcancer.2012.03.004.
5
Treatment of limited disease small cell lung cancer.局限性疾病小细胞肺癌的治疗
Eur J Cancer. 2009 Sep;45 Suppl 1:425-6. doi: 10.1016/S0959-8049(09)70075-9.
6
Targeting an autocrine loop in small-cell lung cancer: irrelevant target or ineffective drug?
Clin Lung Cancer. 2010 Jul 1;11(4):222. doi: 10.3816/CLC.2010.n.027.
7
[Small Cell Lung Cancer].
Pneumologie. 2021 Apr;75(4):304-318. doi: 10.1055/a-0982-0375. Epub 2021 Apr 19.
8
[Immuno-checkpoint inhibitor resistance and strategy in lung cancer].[肺癌中的免疫检查点抑制剂耐药性及策略]
Zhonghua Jie He He Hu Xi Za Zhi. 2020 Jul 12;43(7):603-606. doi: 10.3760/cma.j.cn112147-20200312-00319.
9
Mesothelioma and small cell lung cancer.间皮瘤和小细胞肺癌。
J Thorac Oncol. 2011 Nov;6(11 Suppl 4):S1825-6. doi: 10.1097/01.JTO.0000407574.52702.92.
10
Targeted Therapy and Immune Therapy for Small Cell Lung Cancer.小细胞肺癌的靶向治疗和免疫治疗。
Curr Treat Options Oncol. 2018 Sep 10;19(11):53. doi: 10.1007/s11864-018-0568-3.
引用本文的文献
1
Targeting Senescence in Oncology: An Emerging Therapeutic Avenue for Cancer.肿瘤学中的衰老靶向治疗：癌症治疗的新兴途径
Curr Oncol. 2025 Aug 18;32(8):467. doi: 10.3390/curroncol32080467.
2
BH3-mimetics: recent developments in cancer therapy.BH3 模拟物：癌症治疗的最新进展。
J Exp Clin Cancer Res. 2021 Nov 9;40(1):355. doi: 10.1186/s13046-021-02157-5.
3
Targeting the BCL-2-regulated apoptotic pathway for the treatment of solid cancers.针对 BCL-2 调控的凋亡途径治疗实体瘤。
Biochem Soc Trans. 2021 Nov 1;49(5):2397-2410. doi: 10.1042/BST20210750.
4
Autophagy sensitivity of neuroendocrine lung tumor cells.神经内分泌肺肿瘤细胞的自噬敏感性。
Int J Oncol. 2013 Dec;43(6):2031-8. doi: 10.3892/ijo.2013.2136. Epub 2013 Oct 11.
本文引用的文献
1
Randomized phase II study of carboplatin and etoposide with or without obatoclax mesylate in extensive-stage small cell lung cancer.卡铂和依托泊苷联合或不联合甲磺酸 obatoclax 治疗广泛期小细胞肺癌的随机 II 期研究。
Lung Cancer. 2014 Sep;85(3):420-8. doi: 10.1016/j.lungcan.2014.05.003. Epub 2014 May 13.
2
Ipilimumab in combination with paclitaxel and carboplatin as first-line therapy in extensive-disease-small-cell lung cancer: results from a randomized, double-blind, multicenter phase 2 trial.伊匹单抗联合紫杉醇和卡铂作为广泛期小细胞肺癌的一线治疗：一项随机、双盲、多中心 2 期临床试验的结果。
Ann Oncol. 2013 Jan;24(1):75-83. doi: 10.1093/annonc/mds213. Epub 2012 Aug 2.
3
A crucial requirement for Hedgehog signaling in small cell lung cancer.Hedgehog 信号通路在小细胞肺癌中的关键作用。
Nat Med. 2011 Oct 9;17(11):1504-8. doi: 10.1038/nm.2473.
4
Immunization with N-propionyl polysialic acid-KLH conjugate in patients with small cell lung cancer is safe and induces IgM antibodies reactive with SCLC cells and bactericidal against group B meningococci.用 N-丙酰化多涎酸-KLH 缀合物免疫小细胞肺癌患者是安全的，可诱导与小细胞肺癌细胞反应的 IgM 抗体，并对 B 群脑膜炎球菌具有杀菌作用。
Cancer Immunol Immunother. 2012 Jan;61(1):9-18. doi: 10.1007/s00262-011-1083-6. Epub 2011 Aug 3.
5
Cancer statistics, 2011: the impact of eliminating socioeconomic and racial disparities on premature cancer deaths.癌症统计数据，2011 年：消除社会经济和种族差异对癌症过早死亡的影响。
CA Cancer J Clin. 2011 Jul-Aug;61(4):212-36. doi: 10.3322/caac.20121. Epub 2011 Jun 17.
6
A phase II study of obatoclax mesylate, a Bcl-2 antagonist, plus topotecan in relapsed small cell lung cancer.Obatoclax 甲磺酸盐联合拓扑替康治疗复发性小细胞肺癌的 II 期研究。
Lung Cancer. 2011 Dec;74(3):481-5. doi: 10.1016/j.lungcan.2011.05.005. Epub 2011 May 26.
7
Effects of the Hedgehog pathway inhibitor GDC-0449 on lung cancer cell lines are mediated by side populations. hedgehog 通路抑制剂 GDC-0449 通过侧群细胞对肺癌细胞系的作用。
Clin Exp Med. 2012 Mar;12(1):25-30. doi: 10.1007/s10238-011-0135-8. Epub 2011 Apr 26.
8
Phase I clinical study of Seneca Valley Virus (SVV-001), a replication-competent picornavirus, in advanced solid tumors with neuroendocrine features.具有神经内分泌特征的晚期实体瘤患者中复制型小核糖核酸病毒（SVV-001）的 I 期临床研究。
Clin Cancer Res. 2011 Feb 15;17(4):888-95. doi: 10.1158/1078-0432.CCR-10-1706. Epub 2011 Feb 8.
9
Navitoclax enhances the efficacy of taxanes in non-small cell lung cancer models.纳维托克拉克斯增强了紫杉烷类药物在非小细胞肺癌模型中的疗效。
Clin Cancer Res. 2011 Mar 15;17(6):1394-404. doi: 10.1158/1078-0432.CCR-10-2353. Epub 2011 Jan 10.
10
The molecular basis of synergism between carboplatin and ABT-737 therapy targeting ovarian carcinomas.针对卵巢癌的卡铂和 ABT-737 联合治疗的协同作用的分子基础。
Cancer Res. 2011 Feb 1;71(3):705-15. doi: 10.1158/0008-5472.CAN-10-3174. Epub 2010 Dec 17.
Zotero 插件